Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, Oct. 21, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sage Therapeutics, Inc. ("Sage" or the "Company") ( SAGE) investors of a class action representing investors that bought securities April 12, 2021 and July 23, 2024, inclusive (the "Class Period"). Sage investors have until October 28, 2024 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
Sage Therapeutics is a biopharmaceutical company focused on developing and commercializing medicines for brain health. The class action lawsuit against Sage Therapeutics highlights several key projects, including zuranolone (SAGE-217/BIIB125), a neuroactive steroid being developed for postpartum depression (PPD) and major depressive disorder (MDD) in partnership with Biogen Inc.; SAGE-718 (dalzanemdor), an oral medication that acts as a positive allosteric modulator of the N-methyl-D-aspartate receptor, aimed at treating mild cognitive impairment (MCI) associated with Parkinson’s Disease (PD); and SAGE-324 (BIIB124), an investigational oral drug for essential tremor (ET), also developed in collaboration with Biogen.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
[email protected]
310-692-8883
www.portnoylaw.com
Attorney Advertising
